Pure Global
NCT02064764

Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation

Medtronic Vascular·ClinicalTrials.gov·device·Device trialCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Atrial Fibrillation,Hypertension
Drug/Device/Intervention
Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Medtronic Vascular
Location
Sacramento,Burlington,Marquette,New York,Columbus,Doylestown,Pittsburgh,Seattle,Seattle,Homburg, Germany,United States of America
Timeline & enrollment
Phase
N/A
Start date
Feb 01, 2015
End date
Apr 19, 2021
Enrollment
102 participants
Primary outcome

Safety composite events,Rate of chronic treatment success between study arms

Summary

The purpose of this clinical study is to evaluate the feasibility of performing both renal
 nerve denervation and pulmonary vein isolation on the same patient with the intent of
 characterizing both safety and effectiveness in a paroxysmal and persistent atrial
 fibrillation population with hypertension. To assess safety, the study will measure the
 occurrence of a composite safety endpoint and, to assess effectiveness, the study will
 measure freedom of chronic treatment failure through a minimum of six months of follow-up.

ICD-10 classifications
Chronic atrial fibrillationPersistent atrial fibrillationParoxysmal atrial fibrillationAtrial fibrillation and flutterAtrial fibrillation and atrial flutter, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02064764
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT02064764 through Pure Global AI's free database. This phase not specified trial is sponsored by Medtronic Vascular and is currently Completed. The study focuses on Atrial Fibrillation,Hypertension. Target enrollment is 102 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.